Drug Utilization Review (DUR) Meeting Minutes
February 13th, 2006

Members Present: Albert Samuelson, Greg Pfister, John Savageau, Patricia Churchill, Carrie Sorenson, Cheryl Huber, Leann Ness, Norman Byers, Scott Setzepfandt, Gary Betting, Bob Treitline

Medicaid Pharmacy Department: Brendan Joyce

HID Staff Present: Candace Rieth

Members Absent: Jay Huber

Chair J. Savageau called the meeting to order at 1:00pm and asked for a motion to approve the minutes from the November 7th, 2005 meeting. N. Byers moved that the minutes be approved and C. Huber seconded the motion. The chair called for a voice vote to approve the minutes, which passed with no audible dissent.

Budget Update:
B. Joyce reported the appropriations as of 12/31/05 were $20,712,942. Actual expenditures were $20,564,342.

Review of Acto*plus* met:
C. Rieth reviewed Acto*plus* met. The board approved to place this medication on prior authorization in November and this is the 2nd review. Actos alone is a once a day dose; in combination with metformin, there is concern that Actos will become a twice a day dosed medication to ensure appropriate metformin dose. There was no public comment on Acto*plus* met. N. Byers made a motion to place Acto*plus* met on prior authorization. A. Samuelson seconded the motion; the motion was approved by voice vote with no audible dissent.

Yearly review of Prior Authorization
Legislation requires a yearly review of the status of prior authorization. C. Rieth reviewed 3 classes, Antihistamines, COXII/NSAIDs, and Proton Pump Inhibitors. Cost avoidance numbers, market share reports and prior authorization forms and criteria were reviewed. Savings through November 2005 were approximately 2.9 million dollars.

SROA Physician Survey:
At the November DUR meeting, the board voted to send SROA letters and surveys to physicians prescribing these opioids on what appeared to be a prn basis. C. Rieth gave the board an update on the mailing. The first week of January, 132 letters were mailed and as of February 10th, 116 surveys were returned. These surveys will be reviewed and the information will be presented at the May meeting.

'I Confirm' Effect on Prior Authorization
B. Joyce reviewed the 'I Confirm' statement that is currently on the prior authorization request forms. A graph shows that the number of PAs approved based on the 'I Confirm' statement have progressively grown over the last 6 months. Chair J. Savageau made a statement that the ARB percentages had increased to greater than 50% in the short time that the class has been on PA. The chair made the statement that this contradicts what is shown in the literature. J. Savageau recommended that the Department watch the progression closely and suggested that the Department act upon the increased growth.

Review Sedative/Hypnotic Agents
C. Rieth reviewed the Sedative/Hypnotic class of medications. The suggested criteria for PA would require a failure of Ambien (Zolpidem) before other single source Sedative/Hypnotics would be covered. A. Samuelson requested more information be provided at the May meeting regarding usage of this class. Market share information will also be provided. There was public comment by Tim Butler, Account and Leadership Development Director for Sepracor. He spoke against the board implementing a prior authorization of Sedative/Hypnotics. Janet Raddatz spoke, representing Sanofi Aventis. She reviewed Ambien related information with the board. Gary Dawson, representing Takeda, reviewed Rozerem related information with the board. N. Byers made a motion to proceed with the PA form and criteria included in the review. A. Samuelson seconded the motion. This topic will be brought up again at the next board meeting for finalization.

Review of Growth Hormone and Related Products
C. Rieth reviewed growth hormone and related products. Placing growth hormone products and IGF-1 products on prior authorization would allow the Department to review each claim for clinical appropriateness. There was no public comment on Growth Hormone and Related Products.
G. Pfister made a motion to place growth hormone and related products on the prior authorization program. C. Huber seconded the motion. This topic will be brought up again at the next board meeting for finalization.

Review of Recommended Criteria:
B. Joyce advised the board that the enclosed recommended RDUR criteria are developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These criteria will be added to the current set of criteria, and will be used in future RDUR cycles. C. Huber moved to approve the new criteria and P. Churchill seconded the motion. The motion was approved by voice vote with no audible dissent

The next DUR board meeting will be May 1st, 2006. A. Samuelson made a motion to adjourn the meeting. C. Huber seconded. Chair J. Savageau adjourned the meeting at 2:40 pm.